Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00481455
Other study ID # ME-CLN-007
Secondary ID
Status Completed
Phase Phase 2
First received May 30, 2007
Last updated November 24, 2008
Start date April 2007
Est. completion date October 2008

Study information

Verified date November 2008
Source CASI Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date October 2008
Est. primary completion date September 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. A histologically confirmed diagnosis of a recurrent/progressive primary WHO grade IV malignant glioma (glioblastoma multiforme or gliosarcoma). Patients with recurrent disease whose diagnostic pathology confirmed WHO grade IV malignant glioma (glioblastoma multiforme or gliosarcoma) will not need re-biopsy. Patients with prior low-grade glioma are eligible if histologic assessment demonstrates transformation to WHO grade IV malignant glioma. Pathology must be confirmed at Duke University Medical Center

2. Male or female, aged greater than or equal to 18 years.

3. An interval of at least 2 weeks between prior surgical resection (if conducted) or any major surgery or 4 weeks between prior radiotherapy or chemotherapy (except nitrosoureas which require 6 weeks) and enrollment in this protocol unless there is unequivocal evidence of tumor progression and the patient has recovered from toxicities associated with those therapies. However, patients treated with chemotherapeutic agents such as VP-16 who would normally be retreated after shorter intervals (e.g. 21 days on, 7 days off schedule) may be treated at the usual starting time even if less than 4 weeks from the last prior dose of chemotherapy.

4. Karnofsky performance score greater than or equal to 70%.

5. Hematocrit > 29%, absolute neutrophil count > 1,500 cells/*L, platelets > 100,000 cells/*L.

6. Serum creatinine < 1.5 X upper limit of normal (ULN), serum glutamic oxaloacetic transaminase < 2.5 X ULN; and bilirubin < 1.5 times ULN.

7. Signed informed consent form and authorization for use and disclosure of protected health information approved by the Institutional Review Board (IRB) prior to patient entry.

8. If sexually active, patients must use contraceptive measures for the duration of the treatments and for 4 weeks following end of study medication.

Exclusion Criteria:

1. Current, active systemic bleeding or excessive risk of bleeding as defined by the following: stroke within the previous 6 months, history of central nervous system or intraocular bleed, history of septic endocarditis or evidence of intratumor hemorrhage on pretreatment diagnostic imaging, except for stable post operative grade 1 hemorrhage.

2. Female patients who are pregnant or breastfeeding or adults of reproductive potential not employing an effective method of birth control. (Women of childbearing potential must have a negative pregnancy test within 48 hours prior to administration of study medication).

3. Concurrent severe and/or uncontrolled medical disease (i.e. uncontrolled diabetes, congestive cardiac failure, myocardial infarction within 6 months, poorly controlled hypertension, history of labile hypertension, history of poor compliance with antihypertensive regimen, chronic renal disease, or active uncontrolled infection) that could compromise participation in the study.

4. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study medication (i.e. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, bowel obstruction, or inability to swallow the liquid).

5. Requirement for therapy with coumadin (warfarin sodium).

6. Patient is < 1 year free of another primary malignancy except if the other primary malignancy is not currently clinically significant or requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.

7. Patients unwilling to or unable to comply with the protocol.

8. Grade 2 or greater peripheral sensory neuropathy

Study Design

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Panzem NCD
2000 mg q8h, continuous dosing in 28 day cycles
Temozolomide
Fixed dose

Locations

Country Name City State
United States The Brain Tumor Center, Duke University Medical Center Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
CASI Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 6-month progression free survival and median overall survival for patients receiving at least one dose Every 2 cycles No
See also
  Status Clinical Trial Phase
Completed NCT00597493 - Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM Phase 2
Completed NCT00379470 - Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) Phase 3
Recruiting NCT01737346 - Procarbazine and Lomustine in Recurrent Glioblastoma Phase 2
Active, not recruiting NCT01464177 - Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme Phase 2
Active, not recruiting NCT00562419 - CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan Phase 2
Completed NCT00071539 - Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors Phase 2
Active, not recruiting NCT02062827 - Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma Phase 1
Completed NCT00509301 - Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme Phase 1
Recruiting NCT05868083 - The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma Phase 1
Completed NCT01576666 - Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors Phase 1
Completed NCT01738646 - Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Phase 2
Completed NCT00306618 - Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma Phase 2
Completed NCT01934361 - Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme Phase 1
Terminated NCT04915404 - Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) Phase 1/Phase 2
Terminated NCT01756729 - Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Phase 4
Completed NCT00747253 - Monteris AutoLITTâ„¢ FIM Safety Trial for Recurrent/Progressive Brain Tumors Phase 1
Completed NCT00883298 - Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme Phase 2
Recruiting NCT03423628 - A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer Phase 1
Recruiting NCT04689087 - A Prospective, Open-label, Single-arm Clinical Study N/A